# Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity

> **NCT00340080** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1806 (—)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Abacavir

## Key facts

- **NCT ID:** NCT00340080
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 1806 (—)
- **Last updated:** 2010-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00340080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00340080, "Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00340080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*